Celine Halioua and her company Loyal are on track to deliver a drug next year that could help dogs live longer.
Loyal’s therapy is aimed at senior dogs (10+ years of age) that weigh more than 14 pounds. It’s a pill that the dogs will take daily and that’s designed to extend the dogs’ lifespan by at least a year. To get to this point, Loyal conducted a massive clinical trial with 1,300 dogs, and the FDA has liked what it’s seen so far.
Halioua joins the podcast this week to chat about her unique approach to cracking the longevity field.
Loyal has been betting that it will be easier to prove that longevity drugs work (and get regulators on board) by starting with dogs instead of humans. The company has been testing promising longevity compounds and now has three therapies in its drug pipeline aimed at our canine friends.
I’ve known Halioua for several years now. She’s one of the deepest, most pragmatic thinkers in the longevity field and approaches her work without the hype and false promises that often accompany some of our live forever gurus.
We get into her life, her work, some of the oddities of running a company in San Francisco and what it’s like to be in bio-tech during the great AI hype era.
Enjoy!
The Core Memory podcast is sponsored by Brex, the intelligent finance platform. Like thousands of ambitious, innovative companies, we run on Brex so we can spend smarter and move faster. And you can too. Learn more at www.brex.com/corememory
The podcast is also made possible by E1 Ventures, which backs the most ambitious founders and start-ups.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
www.corememory.com/subscribe
